DepoVax is a patented vaccine delivery formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system. The result is a strong, specific and sustained immune response with the capability for single-dose effectiveness.
As a versatile platform with potential applications across a broad range of human and animal health applications, Immunovaccine is actively engaged in seeking collaborations to evaluate the DepoVax technology in various areas. Partnership, collaboration and licensing opportunities are available through our DepoVax Challenge OR to advance Immunovaccine’s vaccine products.
1. DepoVax™ Challenge
– Our DepoVax Challenge is a research partnership where you provide Immunovaccine with your antigens and we incorporate them into our DepoVax® platform. We then provide you with the new vaccine formulation for testing in your validated models to compare the results head-to-head with your previous formulations. This may yield interesting data to advance your vaccine product and/or create next-generation products for your company. For more information on the DepoVax challenge click here
– DPX-0907 is a therapeutic cancer vaccine candidate containing seven antigens indicated for breast, ovarian and prostate cancer. These seven antigens are involved in major cancer cell pathways and are present on the cancer cell surface. DPX-0907 has completed a Phase I clinical trial at five U.S. sites and is Phase II ready. For a complete breakdown of the positive results from this study, please visit our DPX-0907 page here
. We are currently seeking partners to develop DPX-0907 for follow-on clinical trials.
To build on the results from this initial study and support partnering of the program, Immunovaccine signed an Investigator-Initiated Study Agreement to evaluate DPX-0907 at the Busto Arsizio Hospital in Milan Italy. The Company expects the Phase I/II study in patients with breast and ovarian cancer to be initiated during the fourth quarter of 2013.
– DPX-Survivac is a survivin-based therapeutic cancer vaccine. As survivin is a critical molecule for cancer cell survival and highly associated with many types of tumor cells, it is considered a universal cancer antigen. While DPX-Survivac has broad market potential to target at least nine different cancers, Immunovaccine is developing DPX-Survivac to treat ovarian cancer in initial Phase I/II clinical trials. We are presently seeking partners to develop DPX-Survivac for additional indications. For more information on DPX-Survivac click here
For partnering opportunities, please contact:
Vicki Morgan, Vice President, Business Development 902-492-1819, ext. 4 or email@example.com